JPMorgan Chase & Co. Boosts Holdings in Prestige Consumer Healthcare Inc. $PBH

JPMorgan Chase & Co. lifted its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 30.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 459,228 shares of the company’s stock after buying an additional 106,224 shares during the period. JPMorgan Chase & Co.’s holdings in Prestige Consumer Healthcare were worth $28,656,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. First Horizon Corp purchased a new position in Prestige Consumer Healthcare in the third quarter valued at approximately $32,000. Hantz Financial Services Inc. raised its stake in shares of Prestige Consumer Healthcare by 373.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 682 shares of the company’s stock valued at $43,000 after acquiring an additional 538 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in shares of Prestige Consumer Healthcare during the 2nd quarter valued at $46,000. First Horizon Advisors Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 294.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock valued at $48,000 after acquiring an additional 447 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its position in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare News Roundup

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Bleakley Financial Group reported a new purchase of 10,912 PBH shares (~$681,000), signaling fresh institutional buying interest in the stock. Bleakley Investment
• Positive Sentiment: Zacks bumped a few quarterly estimates: Q4 2026 was raised to $1.59 (from $1.54), Q3 2027 to $1.21 (from $1.20) and Q4 2027 to $1.32 (from $1.26) — small upside revisions that suggest pockets of strength in certain quarters.
• Neutral Sentiment: Zacks Research continues to carry a “Hold” rating on PBH even as it updates estimates; the firm’s commentary so far is a recalibration of numbers rather than a rating change. Consensus full‑year EPS referenced by Zacks remains near $4.50 for the current year.
• Negative Sentiment: Zacks pared several near‑term and fiscal forecasts, which is the main driver of downward pressure: Q1 2027 EPS cut to $1.09 (from $1.24), Q1 2028 to $1.14 (from $1.26), Q2 2028 to $1.30 (from $1.33), Q3 2028 to $1.26 (from $1.28), FY2027 to $4.77 (from $4.84) and FY2028 to $5.06 (from $5.19). Those trims signal slower expected earnings growth and likely explain why the stock is underperforming today.

Analysts Set New Price Targets

Several equities analysts recently commented on PBH shares. Jefferies Financial Group reduced their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Canaccord Genuity Group decreased their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Finally, Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $80.60.

Insider Transactions at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total transaction of $65,930.00. Following the transaction, the vice president directly owned 41,048 shares in the company, valued at approximately $2,706,294.64. This trade represents a 2.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

PBH opened at $69.30 on Friday. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The business’s 50 day moving average is $65.26 and its 200-day moving average is $63.47. The stock has a market cap of $3.28 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 2.18 and a beta of 0.43. Prestige Consumer Healthcare Inc. has a twelve month low of $57.25 and a twelve month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). The company had revenue of $283.44 million during the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).